Healthcare Industry News: Concert Pharmaceuticals
News Release - October 6, 2008
Steven Bernitz Joins Concert Pharmaceuticals as Chief Business OfficerLEXINGTON, Mass.--(HSMN NewsFeed)--Concert Pharmaceuticals, Inc. today announced that Steven B. Bernitz has joined the company as its Senior Vice President and Chief Business Officer. In this role, he will be a member of Concert’s executive management team, designing and implementing strategic planning initiatives and having overall responsibility for Concert’s business development activities. Mr. Bernitz replaces Jeffrey Williams who now serves as a consultant to the company.
“It is a great pleasure to welcome Steve to our team,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Steve brings a strong skill set to Concert as well as a proven track record of success in the biotechnology industry. We expect him to play a key role across Concert’s corporate and business development activities.”
Concert also announced today that it will be participating at the 16th Annual BioPartnering Europe conference being held October 12 – 14, 2008 in London. Mr. Bernitz will present an overview of Concert on Tuesday, October 14, 2008 at 9:15 a.m. BST at the conference.
Mr. Bernitz has over 15 years experience in the pharmaceutical and biotechnology industry. He brings extensive experience in business, corporate and product development as well as commercial operations to Concert. Most recently he served as Chief Executive Officer of Histogenics Corporation. Before Histogenics, he held the position Senior Vice President, Business and Commercial Development at Coley Pharmaceutical Group, where he led a $515 million licensing deal with Pfizer, which subsequently acquired Coley. Mr. Bernitz was also a senior executive at Organogenesis, and has held senior positions in business development, alliance management and product development with Dyax Corp. and Merck & Co. Prior to his life sciences experience he worked in private equity and was a consultant at McKinsey & Co, Inc. Mr. Bernitz received his B.S. summa cum laude from Tufts University where he was elected to Phi Beta Kappa, and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.
Concert Pharmaceuticals, Inc. is a clinical stage biotechnology company dedicated to creating medically and commercially important new medicines through a novel approach utilizing the naturally-occurring element deuterium. Concert applies its innovative platform to create highly differentiated compounds based on well-understood biological targets and drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while reducing R&D risk, time, and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including vasomotor symptoms, HIV/AIDS and fibrotic diseases, among others. Since its inception in 2006, Concert has raised more than $96 million and has been financed by leading venture capitalists and institutional investors. A complete listing of Concert’s shareholders and additional corporate information is available online at http://www.concertpharma.com.
CoNCERT and Concert Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc.
Source: Concert Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.